The discovery of the NRF2 oncogenic mechanism as an important driving mechanism in Taiwan and the discovery of the patient subgroup system offers new angles for deriving future counteracting strategies against specific lung cancer mechanisms. The gene discussed is NFE2L2; the disease is lung carcinoma.